CNTX vs. UNCY, MTCR, CBIO, PHAT, ZYME, SVRA, HRTX, ALXO, OLMA, and TVTX
Should you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Unicycive Therapeutics (UNCY), Metacrine (MTCR), Catalyst Biosciences (CBIO), Phathom Pharmaceuticals (PHAT), Zymeworks (ZYME), Savara (SVRA), Heron Therapeutics (HRTX), ALX Oncology (ALXO), Olema Pharmaceuticals (OLMA), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Unicycive Therapeutics (NASDAQ:UNCY) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.
Unicycive Therapeutics currently has a consensus price target of $5.30, suggesting a potential upside of 502.27%. Context Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 203.03%. Given Context Therapeutics' higher probable upside, equities analysts plainly believe Unicycive Therapeutics is more favorable than Context Therapeutics.
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 24.1% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Unicycive Therapeutics has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500.
Context Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Unicycive Therapeutics received 7 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 67.74% of users gave Unicycive Therapeutics an outperform vote while only 66.67% of users gave Context Therapeutics an outperform vote.
Context Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.
In the previous week, Unicycive Therapeutics had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 7 mentions for Unicycive Therapeutics and 3 mentions for Context Therapeutics. Unicycive Therapeutics' average media sentiment score of 0.70 beat Context Therapeutics' score of 0.24 indicating that Context Therapeutics is being referred to more favorably in the news media.
Summary
Unicycive Therapeutics beats Context Therapeutics on 12 of the 14 factors compared between the two stocks.
Get Context Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Context Therapeutics Competitors List
Related Companies and Tools
